Albireo News Releases http://ir.albireopharma.com/ Albireo News Releases en Albireo Reports First Quarter 2019 Financial Results http://ir.albireopharma.com/news-releases/news-release-details/albireo-reports-first-quarter-2019-financial-results Odevixibat Phase 3 PEDFIC 1 PFIC trial continues to enroll as planned Initiation of additional cohort of PFIC patients in PEDFIC 2 extension trial announced Odevixibat pivotal trial in biliary atresia on track to begin H2 2019 IND cleared to initiate elobixibat Phase 2 trial in NASH Q2 2019 Thu, 09 May 2019 07:30:00 -0400 Albireo News Releases 11766 Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast http://ir.albireopharma.com/news-releases/news-release-details/albireo-report-first-quarter-2019-financial-results-and-host BOSTON , May 02, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10 a.m. Thu, 02 May 2019 08:30:00 -0400 Albireo News Releases 11756 Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019 http://ir.albireopharma.com/news-releases/news-release-details/albireo-presents-data-a4250-children-biliary-atresia-and - Reduction in serum bile acids and pruritus observed in both populations –  - Alagille abstract selected for inclusion in ’Best of ILC’ –  - Albireo plans to initiate second A4250 pivotal program in biliary atresia second half of 2019 – BOSTON , April 13, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Sat, 13 Apr 2019 07:30:00 -0400 Albireo News Releases 11716 Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH http://ir.albireopharma.com/news-releases/news-release-details/albireo-announces-fda-clearance-ind-commence-phase-2-trial – Initiation of Phase 2 clinical trial expected in Q2 2019 –  – IBAT inhibition has potential to impact key markers of NASH – BOSTON , April 11, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid Thu, 11 Apr 2019 07:30:00 -0400 Albireo News Releases 11711 Albireo to Present at Investor Conferences in April http://ir.albireopharma.com/news-releases/news-release-details/albireo-present-investor-conferences-april BOSTON , April 01, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April: H.C. Wainwright & Co. Mon, 01 Apr 2019 07:30:00 -0400 Albireo News Releases 11701 Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress™ 2019 http://ir.albireopharma.com/news-releases/news-release-details/albireo-present-clinical-data-a4250-alagille-syndrome-and BOSTON , March 27, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that results from its completed Phase 2 clinical trial of lead product candidate A4250 in children with Wed, 27 Mar 2019 08:48:00 -0400 Albireo News Releases 11686 Albireo Expands Executive Leadership Team with Appointment of Pamela Stephenson as Chief Commercial Officer http://ir.albireopharma.com/news-releases/news-release-details/albireo-expands-executive-leadership-team-appointment-pamela -- Significant recent rare disease product launch and access experience -- -- Key addition as Albireo prepares for commercialization of A4250 -- BOSTON , March 21, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel Thu, 21 Mar 2019 08:30:00 -0400 Albireo News Releases 11671 Albireo Reports Year-End 2018 Financial Results and Provides Pipeline Update http://ir.albireopharma.com/news-releases/news-release-details/albireo-reports-year-end-2018-financial-results-and-provides - A4250 Phase 3 PFIC pivotal program on target for end of ‘19/early ’20 topline readout - - Plan to initiate second A4250 pivotal program in biliary atresia - - Plan to initiate Phase 2 study with elobixibat in NASH - - Management to host conference call and webcast today at 8:30 a.m. Thu, 07 Mar 2019 07:30:00 -0500 Albireo News Releases 11651 Albireo to Present at Cowen and Company 39th Annual Health Care Conference http://ir.albireopharma.com/news-releases/news-release-details/albireo-present-cowen-and-company-39th-annual-health-care BOSTON , March 04, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the Cowen and Company Mon, 04 Mar 2019 08:30:00 -0500 Albireo News Releases 11626 Albireo Recognizes Rare Disease Day and Highlights Urgent Need to Support Families Affected by Progressive Familial Intrahepatic Cholestasis (PFIC) http://ir.albireopharma.com/news-releases/news-release-details/albireo-recognizes-rare-disease-day-and-highlights-urgent-need Advances in research and efforts to build awareness of life-threatening, rare, pediatric liver disease offer new hope for patients and families BOSTON , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ: ALBO), a clinical-stage orphan pediatric liver disease company developing novel Thu, 28 Feb 2019 08:30:00 -0500 Albireo News Releases 11621